Understanding its intricate molecular mechanisms may unveil new therapeutic targets for inhibiting CHI3L1‐mediated neuronal signalling, offering promising avenues for targeted interventions in MS. This evidence concerns the gene CHI3L1 and myeloid sarcoma.